EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

Core Viewpoint - EyePoint Pharmaceuticals, Inc. has announced a public offering of 12,727,273 shares at a price of $11.00 per share, aiming to raise approximately $140.0 million before expenses [1][2]. Group 1: Offering Details - The offering consists of common stock sold entirely by EyePoint, with the closing expected around October 31, 2024, pending customary conditions [1]. - Underwriters have a 30-day option to purchase an additional 1,909,090 shares at the public offering price [1]. Group 2: Use of Proceeds - Net proceeds from the offering will be utilized to advance clinical development of DURAVYU™ for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), as well as support earlier stage pipeline initiatives and general corporate purposes [2]. Group 3: Company Overview - EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on innovative therapeutics for serious retinal diseases, leveraging its proprietary Durasert E™ technology for sustained intraocular drug delivery [6][7]. - The lead product candidate, DURAVYU™, is currently in Phase 3 trials for wet AMD and Phase 2 trials for DME, with topline data expected in Q1 2025 and 2026 respectively [6][8].